Skip to main content
ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd.
  • Overview
    • News
      • News Releases
      • In the Media
    • Events & Presentations
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
      • Dividend History
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Governance
      • Governance Documents
      • Executive Management
      • Board of Directors
      • Committee Composition
    • Resources
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts

Executive Management

  • Overview
    • News
      • News Releases
      • In the Media
    • Events & Presentations
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
      • Dividend History
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Governance
      • Governance Documents
      • Executive Management
      • Board of Directors
      • Committee Composition
    • Resources
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts

Executive Management Carousel

Portrait

Dr. Jennifer Bath, Chief Executive Officer and President

Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Portrait

Brad McConn, Chief Financial Officer

Brad McConn serves as the Chief Financial Officer for ImmunoPrecise Antibodies. He is responsible for oversight of the company’s financial reporting, financial planning & analysis, and complex accounting research. Prior to his current role he served as the Director of Financial Planning & Analysis for ImmunoPrecise Antibodies, and previously worked as an analyst in the real estate industry, focusing on a broad range of financial processes and business development. He is a CFA® charterholder, and holds a Bachelor of Arts in Mathematics with Minors in Chemistry and Business.

Portrait

Dr. Ilse Roodink, Chief Scientific Officer

Dr. Ilse Roodink serves as Chief Scientific Officer (CSO) of ImmunoPrecise Antibodies, supporting the company’s global research and development teams. Prior to her appointment as CSO, she held different scientific positions at the Company’s Dutch facility in Oss from 2013 until 2021. In her last role as Scientific Director of ImmunoPrecise Europe, Dr. Roodink was overseeing contract research project execution and management and actively involved in the integration of innovative technologies supporting antibody characterization and engineering. Following its establishment in 2019, Dr. Roodink has served as Chairwoman of Talem Therapeutics’ Scientific Advisory Committee, leading the development of Talem’s pipeline assets.

Dr. Roodink graduated from Radboud University of Nijmegen, the Netherlands with a Master’s degree in Biomedical Health Sciences and a Ph.D. in Medical Sciences. Her work, resulting in several peer-reviewed publications, focused on platform development to facilitate the discovery of antibodies specifically recognizing native tumor targets.

Portrait

Kari Graber, VP of Commercial Services

Kari Graber serves as the Vice President of Commercial Services for ImmunoPrecise Antibodies, and is responsible for the overall leadership and implementation of the Project Management program throughout ImmunoPrecise’s global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers, and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Ms. Graber served at Aldevron LLC, where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology and a Minor in Microbiology.

Portrait

Carla Dahl, VP of Marketing

Carla Dahl is an accomplished leader with more than 20 years of strategic brand and marketing experience in the bioscience and healthcare spaces. She has a proven track record of managing major marketing initiatives for medical device launches at both start-up and multi-national companies. Prior to joining ImmunoPrecise Antibodies as the VP of Marketing in 2021, she served as the VP of Marketing at Preceptis Medical, Sr. Director Global Marketing Communication and Marketing Operations at Medtronic, Director Global Marketing at St. Jude Medical, and Director of Marketing at Cardiovascular Systems. Ms. Dahl has a distinctive history of success managing the translation of complex medical and scientific concepts into smart, market-leading brands and omni-channel strategies.

Portrait

Dr. Barry Duplantis, VP of Client Relations

Dr. Barry Duplantis serves as Vice President of Client Relations for ImmunoPrecise Antibodies and is responsible for managing and coordinating all sales- related activities. He is a scientific entrepreneur and business development specialist with over 10 years experience in the commercial application of drug and vaccine discovery platforms. Prior to his appoint to VP of Client Relations he served as the Director of Client Relations for ImmunoPrecise Antibodies (Canada) and was the founder and CEO of DuVax Vaccine and Reagents. Dr. Duplantis obtained his Ph.D. from the Department of Microbiology and Biochemistry at the University of Victoria in 2012 with a focus on intracellular pathogenesis and vaccine development.

Portrait

Dr. Debby Kruijsen, General Manager, ImmunoPrecise Antibodies Europe

Dr. Debby Kruijsen is the General Manager of ImmunoPrecise Antibodies Europe, formerly ModiQuest Research (Oss, The Netherlands), which became part of the ImmunoPrecise family of companies in April 2018.

She began her career in immunology at Utrecht University in the Netherlands. In 2012, she joined ModiQuest Research where she held different scientific and management positions until she became General Manager of ImmunoPrecise Antibodies Europe. Dr. Kruijsen works closely with the executive and global teams to develop and execute business strategies, improve operational efficiencies, and support ImmunoPrecise as an innovative company in the CRO space.

Portrait

Teri Otto, General Manager, ImmunoPrecise Antibodies Canada

Teri Otto is the General Manager of ImmunoPrecise Antibodies Canada (Victoria, BC). She works closely with the executive and internal teams to implement best practices and company strategy. Ms. Otto has held a variety of scientific and management positions prior to her role as General Manager.

Ms. Otto holds a Bachelor of Science in Microbiology and Associate degrees in Psychology and Applied Chemistry/Biochemistry.

ImmunoPrecise Antibodies Ltd.

Follow us

  • follow us on twitter
  • follow us on linkedin
  • follow us on facebook

IR Contact

investors@ipatherapeutics.com

Main Website

https://www.ipatherapeutics.com/

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At ImmunoPrecise Antibodies Ltd., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to ImmunoPrecise Antibodies Ltd. to send you the requested Investor Email Alert updates.

* Required

*
Investor Alert Options
*





Unsubscribe

Email Alert Sign Up Confirmation

Request a meeting with management
  • Privacy Policy
  • Cookies Policy
  • Terms of Use
©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD.
Powered By Q4 Inc. 5.87.0.1 (opens in new window)